Tags

Type your tag names separated by a space and hit enter

Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis.

Abstract

The new coronavirus, COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. Risk factors associated with this disease are age, sex, and the presence of comorbidities, the most common being hypertension, diabetes, and heart disease. The aim of this meta-analysis was to calculate the prevalence and geographical distribution of comorbidities in all patients admitted to intensive care units (ICUs), and the mortality rate of COVID-19. We selected studies based upon epidemiological and clinical descriptions of the patients and mortality from the disease to determine the pooled prevalence of comorbidities in all patients and in mortality cases due to COVID-19. The pooled prevalence was estimated using the random effects model, and odds ratios were used to measure the probability of death for a patient with a comorbidity. The total prevalence of comorbidities in patients with COVID-19 was 42% (95% CI: 25-60), 61% (95% CI: 42-80) in those admitted to the ICU, and 77% (95% CI: 68-86) among death cases; males were the most affected. Hypertension was the most prevalent comorbidity in all three groups studied, accounting for 32%, 26%, and 35%, respectively. The odds ratio of death for a patient with a comorbidity compared to one with no comorbidity was 2.4 (P < 0.0001). The higher the prevalence of comorbidities the higher the odds that the COVID-19 patient will need intensive care or will die, especially if the pre-existing disease is hypertension, heart disease, or diabetes.

Authors+Show Affiliations

Faculdade do Pantanal, Cáceres, Mato Grosso, Brazil.Universidade do Estado de Mato Grosso, Faculdade de Ciências Agrárias e Biológicas, Programa de Pós-Graduação em Ciências Ambientais. Cáceres, Mato Grosso, Brazil.Faculdade do Pantanal, Cáceres, Mato Grosso, Brazil.Centro de Excelência do Instituto Joanna Briggs, Centro Brasileiro para o Cuidado à Saúde Informado por Evidências, São Paulo, São Paulo, Brazil.Universidade do Estado de Mato Grosso, Faculdade de Ciências Agrárias e Biológicas, Programa de Pós-Graduação em Ciências Ambientais. Cáceres, Mato Grosso, Brazil.Universidade Federal de Mato Grosso, Hospital Universitário Júlio Miller, Cuiabá, Mato Grosso, Brazil.

Pub Type(s)

Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

32578683

Citation

Espinosa, Omar Ariel, et al. "Prevalence of Comorbidities in Patients and Mortality Cases Affected By SARS-CoV2: a Systematic Review and Meta-analysis." Revista Do Instituto De Medicina Tropical De Sao Paulo, vol. 62, 2020, pp. e43.
Espinosa OA, Zanetti ADS, Antunes EF, et al. Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis. Rev Inst Med Trop Sao Paulo. 2020;62:e43.
Espinosa, O. A., Zanetti, A. D. S., Antunes, E. F., Longhi, F. G., Matos, T. A., & Battaglini, P. F. (2020). Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis. Revista Do Instituto De Medicina Tropical De Sao Paulo, 62, e43. https://doi.org/10.1590/S1678-9946202062043
Espinosa OA, et al. Prevalence of Comorbidities in Patients and Mortality Cases Affected By SARS-CoV2: a Systematic Review and Meta-analysis. Rev Inst Med Trop Sao Paulo. 2020;62:e43. PubMed PMID: 32578683.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis. AU - Espinosa,Omar Ariel, AU - Zanetti,Andernice Dos Santos, AU - Antunes,Ednardo Fornanciari, AU - Longhi,Fabiana Gulin, AU - Matos,Tatiane Amorim de, AU - Battaglini,Paula Franciene, Y1 - 2020/06/22/ PY - 2020/06/12/received PY - 2020/06/12/accepted PY - 2020/6/25/entrez PY - 2020/6/25/pubmed PY - 2020/7/1/medline SP - e43 EP - e43 JF - Revista do Instituto de Medicina Tropical de Sao Paulo JO - Rev Inst Med Trop Sao Paulo VL - 62 N2 - The new coronavirus, COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. Risk factors associated with this disease are age, sex, and the presence of comorbidities, the most common being hypertension, diabetes, and heart disease. The aim of this meta-analysis was to calculate the prevalence and geographical distribution of comorbidities in all patients admitted to intensive care units (ICUs), and the mortality rate of COVID-19. We selected studies based upon epidemiological and clinical descriptions of the patients and mortality from the disease to determine the pooled prevalence of comorbidities in all patients and in mortality cases due to COVID-19. The pooled prevalence was estimated using the random effects model, and odds ratios were used to measure the probability of death for a patient with a comorbidity. The total prevalence of comorbidities in patients with COVID-19 was 42% (95% CI: 25-60), 61% (95% CI: 42-80) in those admitted to the ICU, and 77% (95% CI: 68-86) among death cases; males were the most affected. Hypertension was the most prevalent comorbidity in all three groups studied, accounting for 32%, 26%, and 35%, respectively. The odds ratio of death for a patient with a comorbidity compared to one with no comorbidity was 2.4 (P < 0.0001). The higher the prevalence of comorbidities the higher the odds that the COVID-19 patient will need intensive care or will die, especially if the pre-existing disease is hypertension, heart disease, or diabetes. SN - 1678-9946 UR - https://cancerres.unboundmedicine.com/medline/citation/32578683/Prevalence_of_comorbidities_in_patients_and_mortality_cases_affected_by_SARS_CoV2:_a_systematic_review_and_meta_analysis_ DB - PRIME DP - Unbound Medicine ER -